VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics
Citation:
Andrews, J.A. and Cudkowicz, M.E. and Hardiman, O. and Meng, L. and Bian, A. and Lee, J. and Wolff, A.A. and Malik, F.I. and Shefner, J.M., VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 259-266Author's Homepage:
http://people.tcd.ie/hardimaoDescription:
PUBLISHED
Author: HARDIMAN, ORLA
Type of material:
Journal ArticleCollections
Series/Report no:
Amyotrophic Lateral Sclerosis and Frontotemporal DegenerationAvailability:
Full text availableDOI:
http://dx.doi.org/10.1080/21678421.2018.1426770Metadata
Show full item recordLicences: